CLINICAL REPORTSFeasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer FAST-nabSaji, Hisashi; Marushima, Hideki; Miyazawa, Tomoyuki; Sakai, Hiroki; Kimura, Hiroyuki; Kurimoto, Noriaki; Nakamura, HaruhikoAuthor Information Department of Chest Surgery, St Marianna University School of Medicine, Kawasaki, Japan Correspondence to Hisashi Saji, MD, PhD, Department of Chest Surgery, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan Tel: +81 449 778 111; fax: +81 449 765 792; e-mail: email@example.com Received January 5, 2017 Accepted April 10, 2017 Anti-Cancer Drugs: August 2017 - Volume 28 - Issue 7 - p 795-800 doi: 10.1097/CAD.0000000000000512 Buy Metrics Abstract The aim of this study was to determine the feasibility of adjuvant administration of nab-paclitaxel (nab-P) plus carboplatin and for completely resected patients with stage IB, II, and IIIA non-small-cell lung cancer (NSCLC) (FAST-nab study, UMIN000011225). Twenty-nine eligible NSCLC patients received surgical resection for pathological stage IB, II, or IIIA, followed by postoperative adjuvant chemotherapy with modified 3-week cycles of either nab-P (100 mg/m2) on days 1 and 8, followed by carboplatin area (area under the curve=6) on day 1. Twenty-two (75.9%) of the 29 patients enrolled completed four cycles of this regimen. The most common grade 3 or 4 adverse event experienced during the nab-P plus carboplatin was neutropenia (34.5%), followed by anemia (13.8%). No grade 3 or 4 nonhematologic adverse event was observed during this chemotherapy. The median time to disease recurrence survival was 21 (95% confidence interval: 16–26) months. The administration of modified nab-P plus carboplatin was considered an attractive alternative regimen that was safe and well tolerated as a postoperative adjuvant chemotherapy for completed resected NSCLC. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.